Cantargia obtains patent approval in China for therapy against IL1RAP in acute lymphoblastic leukemia
The Chinese patent office, State Intellectual Property Office (“SIPO”) has granted formal patent approval for Cantargia AB’s (“Cantargia”) application for use of IL1RAP as target molecule for antibody-based therapy of acute lymphoblastic leukemia (“ALL”).The approved patent with number ZL201080047833.3 provides protection until 2030 and covers Cantargia’s method of using IL1RAP as target molecule for treatment of ALL. Cantargia has previously received patent approvals for IL1RAP as target molecule for antibody-based therapy for various forms of leukemia in Europe, the United States, Japan,